LAVA Therapeutics Files 8-K on Security Holder Votes

TL;DR

LAVA Therapeutics filed an 8-K on Nov 7, 2025, regarding shareholder votes. Keep an eye on what they're voting on.

AI Summary

LAVA Therapeutics N.V. filed an 8-K on November 7, 2025, reporting on matters submitted to a vote of security holders. The filing details the company's principal executive offices located at Yalelaan 62, Utrecht, The Netherlands.

Why It Matters

This filing indicates important corporate actions or decisions that require shareholder approval, which could impact the company's strategic direction and future operations.

Risk Assessment

Risk Level: low — This is a routine corporate filing related to shareholder votes and does not inherently signal significant financial or operational risk.

Key Players & Entities

• LAVA Therapeutics N.V. (company) — Registrant
• November 7, 2025 (date) — Date of Report
• Yalelaan 62, Utrecht, The Netherlands (location) — Principal Executive Offices

FAQ

Filing Documents

• tm2530600d1_8k.htm (8-K) — 40KB
• 0001104659-25-108480.txt ( ) — 205KB
• lvtx-20251107.xsd (EX-101.SCH) — 3KB
• lvtx-20251107_lab.xml (EX-101.LAB) — 33KB
• lvtx-20251107_pre.xml (EX-101.PRE) — 22KB
• tm2530600d1_8k_htm.xml (XML) — 4KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2025 LAVA Therapeutics N.V. (Exact Name of Registrant as Specified in Charter) The Netherlands 001-40241 82-2745484 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Yalelaan 62 Utrecht , The Netherlands 3584 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: Tel: +31 85 016 3100 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each Class TradingSymbol(s) Name of Each Exchange on Which Registered Ordinary Shares, 0.12 par value LVTX Nasdaq Global Select Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company x If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item5.07 Submission of Matters to a Vote of Security Holders. LAVA Therapeutics N.V., a Dutch public limited liability company ( naamloze vennootschap ) (the "Company"), held an extraordinary general meeting of shareholders (the "EGM") on Friday, November 7, 2025, at 2:00 p.m., Central European Summer Time, at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR, Amsterdam, the Netherlands. As of October 10, 2025, the record date for the EGM, there were 26,305,295of the Company's ordinary shares, par value 0.12 per share (the "Shares"), issued and outstanding. At the EGM, a total of 16,693,201 Shares were present in person or by proxy, representing 63.45% of the total number of Shares outstanding and entitled to vote at the EGM and a quorum for all matters before the shareholders as required by the Company's Articles of Association. The results of the matters voted upon and adopted at the EGM are set forth below. (1) Conditional appointment of the following person as executive director of the Company: Nominee Votes For Votes Against Abstain Broker Non-Votes Owen Hughes 16,649,396 9,304 34,501 - (2) Conditional appointment of the following persons as non-executive directors of the Company: Nominee Votes For Votes Against Abstain Broker Non-Votes Thomas Burns 16,649,383 9,317 34,501 - Bradley Sitko 16,647,337 11,320 34,544 - Maricel Montano 16,648,457 11,333 33,411 - (3) Granting of full and final discharge to each member of the Company's board of directors for their acts of management or supervision, as applicable, up to and including the date of the EGM to the fullest extent permitted under applicable law. Votes For Votes Against Abstain Broker Non-Votes 14,901,602 204,004 1,587,595 - (4) Conditional resolution to enter into a Dutch statutory merger of the Company (as disappearing company) with and into LAVA Therapeutics New Topco B.V. ("New Topco") (as acquiring company), with New Topco issuing class A shares in its share capital to the Company's shareholders (other than XOMA Royalty Corporation ("Buyer")) and class B shares in its share capital to Buyer, in accordance with Sections 2:309 et seq. of the Dutch Civil Code as contemplated by and in accordance with the terms of the merger proposal, filed with the Dutch trade register, and accompanying explanatory notes (the "Downstream Merger"). Votes For Votes Against Abstain Broker Non-Votes 16,672,260 12,474 8,467 - (5) Conditional resolution to approve, to the extent required under applicable law and the Company's organizational documents, also within the meaning of Section 2:107a of the Dutch Civil Code, the Downstream Merger and the cancellation of all outstanding class A shares of New TopCo following the effective time of the Downstream Merger. Votes For Votes Against Abstain Broker Non-Votes 16,672,234 12,474 8,493 - Important Additional Information and Where to Find It This Form 8-K is for i

View Full Filing

View this 8-K filing on SEC EDGAR